当前位置：
X-MOL 学术
›
Theranostics
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Safety of panitumumab-IRDye800CW and cetuximab-IRDye800CW for fluorescence-guided surgical navigation in head and neck cancers
Theranostics ( IF 12.4 ) Pub Date : 2018-03-28 , DOI: 10.7150/thno.24487 Rebecca W. Gao , Nutte Teraphongphom , Esther de Boer , Nynke S. van den Berg , Vasu Divi , Michael J. Kaplan , Nicholas J. Oberhelman , Steven S. Hong , Elissa Capes , A. Dimitrios Colevas , Jason M. Warram , Eben L. Rosenthal
Theranostics ( IF 12.4 ) Pub Date : 2018-03-28 , DOI: 10.7150/thno.24487 Rebecca W. Gao , Nutte Teraphongphom , Esther de Boer , Nynke S. van den Berg , Vasu Divi , Michael J. Kaplan , Nicholas J. Oberhelman , Steven S. Hong , Elissa Capes , A. Dimitrios Colevas , Jason M. Warram , Eben L. Rosenthal
|
Purpose: To demonstrate the safety and feasibility of leveraging therapeutic antibodies for surgical imaging.
中文翻译：
帕尼单抗-IRDye800CW和西妥昔单抗-IRDye800CW在头颈癌的荧光引导手术导航中的安全性
目的：证明利用治疗性抗体进行手术成像的安全性和可行性。
更新日期：2018-09-01
中文翻译：
帕尼单抗-IRDye800CW和西妥昔单抗-IRDye800CW在头颈癌的荧光引导手术导航中的安全性
目的：证明利用治疗性抗体进行手术成像的安全性和可行性。
京公网安备 11010802027423号